Home / Research library / TB-500 Fragment (17-23)
TB-500 Fragment (17-23): molecular data, studies & sources
The selected analytical study describes an acetylated thymosin beta-4 active-region fragment under the name TB-500. It concerns detection in equine samples, not a human efficacy trial. A peptide fragment and full-length thymosin beta-4 are distinct identities.
Overview sources: PMID 23084823
Compiled by PeptideTech Editors · Sources checked · Selected bibliography, not a systematic review
Molecular formula, weight & structure
Molecular record not yet resolved
A sufficiently specific molecular record was not resolved for this name. Formula, molecular weight and structure are withheld until the exact sequence, salt or preparation can be verified.
MF: not assigned · MW: not assigned · Structure: not assigned
Registered clinical trials
Studies registered on ClinicalTrials.gov that list TB-500 Fragment (17-23) as an intervention. Studies that only measure the molecule as a biomarker, or use it only as a comparator or background arm for another drug, are excluded. A registration describes a planned or completed protocol; it does not report a result. Active studies are listed first.
1 registered study matched, 1 currently active or recruiting.
- By highest phase
- Phase 2 · 1
- By registry status
- Recruiting · 1
| Study | Phase · status | Conditions | Sponsor · size |
|---|---|---|---|
| TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVDNCT07487363 · start 2026-02-05 · primary completion 2027-02-14 | Phase 1 / Phase 2Recruiting | Atherosclerotic Cardiovascular Diseases · Endothelial Dysfunction | Hudson Biotech80 participants |
Registry check 2026-10-09 · Run this search on ClinicalTrials.gov
Human intervention studies
Selected studies in which participants received TB-500 Fragment (17-23), with their indexed or reviewed study type. Check the original article for the formulation, population and controls. Studies that only measured the molecule, or used it as a comparator, are listed separately below and are not counted as intervention studies.
No human study that administered this compound was retained in this selected bibliography. This is a documented evidence gap in our selection, not proof that no study exists.
Preclinical research, reviews & other publications
Animal studies, laboratory experiments, reviews and other indexed papers answer different questions. A review is secondary evidence; a case report does not estimate how often an outcome occurs.
- Preclinical / laboratory research
Doping control analysis of TB-500, a synthetic version of an active region of thymosin β₄, in equine urine and plasma by liquid chromatography-mass spectrometry.
Ho EN, Kwok WH, Lau MY et al. · Journal of chromatography. A · 2012
Analytical detection of an acetylated thymosin beta-4 fragment in horse urine and plasma. This is not a human treatment trial.
PMID 23084823 · DOI: 10.1016/j.chroma.2012.09.043
TB-500 Fragment (17-23) supplier sources
Scientific sources describe molecules and experiments. The commercial links below identify recorded supplier packages. A publication or chemical database entry does not verify the seller, purity, sterility or contents of a lot. Some links are affiliate links; see our disclosure.
TB-500 Fragment (17-23) for sale: compare prices, sizes and forms from every tracked supplier →
| Supplier | Recorded packages | Example source listing |
|---|---|---|
| American PeptidesUSD | 10mg Vial1 recorded offers | 10mg Vial · $100.00Checked Oct 13, 2026Supplier listing, TB-500 Fragment (17-23) 10mg Vial, American Peptides, opens in a new tab |
| Amino USAUSD | 10mg Vial1 recorded offers | 10mg Vial · $40.00Checked Oct 13, 2026Supplier listing, TB-500 Fragment (17-23) 10mg Vial, Amino USA, opens in a new tab |
Reference sources & further reading
The citations above link directly to publication records. Encyclopedia links are background reading and are not used to establish clinical effectiveness.
Search for additional research
These links run searches; their results have not been individually reviewed and can include unrelated compounds.
Research information is not a dosing guide or a recommendation for personal use. Study findings are specific to the formulation, population and methods tested. Read our source and correction policy.
Related research profiles
AOD-9604
C78H123N23O23S2
1815.1 g/mol · PubChem CID 71300630
2 selected publications · 0 human intervention studies
ARA-290
C51H84N16O21
1257.3 g/mol · PubChem CID 91810664
7 selected publications · 3 human intervention studies · 2 registered trials
Protein / peptide · highest stage: Phase 2
BPC-157
C62H98N16O22
1419.5 g/mol · PubChem CID 9941957
7 selected publications · 1 human intervention study · 3 registered trials
Protein / peptide · highest stage: Phase 1
KPV
C16H30N4O4
342.43 g/mol · PubChem CID 125672
8 selected publications · 0 human intervention studies
LL-37
C205H340N60O53
4493 g/mol · PubChem CID 16198951
4 selected publications · 0 human intervention studies · 2 registered trials
PTD-DBM
Molecular identity needs further verification
3 selected publications · 0 human intervention studies